Jane Street Group, LLC Cel Sci Corp Call Options Transaction History

Jane Street Group, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 16, 2022	SELL	$2.58 - $4.99 $30,960 - $59,880	-12,000 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$3.93 - $7.7 $1.47 Million - $2.89 Million	-375,200 Reduced 96.9%	12,000 $47,000
Q4 2021 Feb 15, 2022	SELL	$7.1 - $12.82 $157,620 - $284,604	-22,200 Reduced 5.42%	387,200 $2.75 Million
Q3 2021 Nov 16, 2021	SELL	$7.64 - $12.49 $1.06 Million - $1.73 Million	-138,700 Reduced 25.31%	409,400 $4.5 Million
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $98,084 - $310,637	11,300 Added 2.11%	548,100 $4.76 Million
Q1 2021 May 18, 2021	BUY	$12.0 - $27.64 $1.76 Million - $4.05 Million	146,600 Added 37.57%	536,800 $8.17 Million
Q4 2020 Feb 17, 2021	BUY	$11.05 - $16.62 $1.5 Million - $2.25 Million	135,500 Added 53.2%	390,200 $4.55 Million
Q3 2020 Nov 17, 2020	BUY	$11.69 - $14.54 $206,913 - $257,357	17,700 Added 7.47%	254,700 $3.25 Million
Q2 2020 Aug 17, 2020	BUY	$9.75 - $17.6 $1.91 Million - $3.44 Million	195,600 Added 472.46%	237,000 $3.54 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $312,156 - $705,870	41,400 New	41,400 $478,000
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $226,127 - $321,835	-33,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $202,200 - $323,520	33,700 New	33,700 $301,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $33.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.